Search This Blog

Thursday, September 22, 2022

GSK, Spero in Exclusive License Agreement for Late-Stage Antibiotic Asset


  • The exclusive license allows GSK to commercialize tebipenem HBr in all territories, except Japan and certain other Asian countries
  • Spero Therapeutics receives $66 million upfront, with potential for future milestone payments, and tiered royalties.
  • GSK to purchase $9 million in shares of Spero common stock

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.